Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19881124 | 0.80 | CYP2A6 (0.56) | CYP2A6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3080071 | 0.79 | CYP2A6 (0.60) | CYP2A6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL4820940 | 0.79 | CYP2A6 (0.60) | CYP2A6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL40953 | 0.78 | CYP2A6 (1.00) | CYP2A6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL11708827 | 0.78 | CYP2A6 (0.64) | CYP2A6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL8996553 | 0.78 | CYP2A6 (0.64) | CYP2A6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL15930269 | 0.78 | CYP2A6 (0.64) | CYP2A6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL30076672 | 0.78 | CYP2A6 (1.00) | CYP2A6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL7974567 | 0.75 | CYP2A6 (0.92) | CYP2A6MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL16693129 | 0.75 | CYP2A6 (0.60) | CYP2A6MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100221646-A1 | HOLOGRAPHIC RECORDING MEDIUM | KABUSHIKI KAISHA TOSHIBA (JP) | 2010-09-02 | — | — | US | claimed |
| CN-111662158-B | Preparation method of axial chiral biaryl compound and chiral fluorenol compound | 武汉大学 | 2021-09-14 | — | — | CN | disclosed |
| EP-3782977-A1 | CYCLOPROPANATION METHOD AND REAGENT | Fundació Privada Institut Català d'Investigació Química (ICIQ) (ES) | 2021-02-24 | — | — | EP | disclosed |
| CN-111662158-A | Preparation method of axial chiral biaryl compound and chiral fluorenol compound | 武汉大学 | 2020-09-15 | — | — | CN | disclosed |
| US-20180127447-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH | 2018-05-10 | — | — | US | disclosed |
| US-9850268-B2 | Metathesis catalysts and methods thereof | TRUSTEES OF BOSTON COLLEGE (US) | 2017-12-26 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160194343-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-07 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-7238695-B2 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7220765-B2 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) | 2007-05-22 | — | — | US | disclosed |
| WO-2007035841-A9 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS INC (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | BEYONDSPRING PHARMACEUTICALS, INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | BEYONDSPRING PHARMACEUTICALS, INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2007035841-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE | NEREUS PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194343-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | INF2, AFF2, KRAS | CYP2A6 271/4885MAPT 4608/4885ALDH1A1 296/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | CYP2A6 764/4885MAPT 3880/4885ALDH1A1 451/4885 |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | CYP2A6 1294/4885MAPT 3175/4885ALDH1A1 683/4885 |
| US-20180127447-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | INF2, AFF2, KRAS | CYP2A6 271/4885MAPT 4608/4885ALDH1A1 296/4885 |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | MKI67, HPGDS, HCCS | CYP2A6 1352/4885MAPT 4146/4885ALDH1A1 901/4885 |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SSTR2, SSTR5, SSTR3 | CYP2A6 912/4885MAPT 2851/4885ALDH1A1 812/4885 |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | CYP2A6 567/4885MAPT 2416/4885ALDH1A1 1638/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | CYP2A6 3901/4885MAPT 4377/4885ALDH1A1 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.